In short
XEN-D0501 is an investigational substance that blocks TRPV1 receptors, which are involved in bladder sensation and contraction. It is being studied in a Phase 1 clinical trial in 46 participants with obesity, authorised in the EU, and has previously been investigated in a Phase 2a trial for idiopathic overactive bladder (OAB). The current trial focuses on safety, tolerability, pharmacokinetics and efficacy over 12 weeks of oral dosing.
Key points
- XEN-D0501 is a potent and selective TRPV1 receptor antagonist.
- The current EU trial is Phase 1, randomised, double-blind and placebo-controlled.
- It enrols 46 participants with obesity and lasts 12 weeks.
- The trial measures adverse events, vital signs, ECG and laboratory changes.
- An earlier Phase 2a trial studied XEN-D0501 in idiopathic overactive bladder.
- XEN-D0501 is given orally; the OAB trial used twice-daily dosing.
What is XEN-D0501?
XEN-D0501 is an investigational substance described in the sources as a potent and selective antagonist of TRPV1 receptors. TRPV1 is a receptor involved in monitoring bladder volume and the amplitude of bladder contraction. The substance is not authorised as a medicine; it is being studied in clinical trials. The current EU record lists it under the name XEN-D0501, given orally.
How does XEN-D0501 work?
XEN-D0501 works by blocking TRPV1 receptors. These receptors are involved in the mechanism that monitors bladder volume and the amplitude of bladder contraction. By acting as an antagonist at these receptors, XEN-D0501 is thought to reduce the signals that lead to urinary symptoms in overactive bladder. The current obesity trial does not state a specific mechanism for weight effects; its focus is on safety, tolerability, pharmacokinetics and efficacy in obese participants.
Which conditions is XEN-D0501 used or studied for?
- Obesity: the current Phase 1 trial is evaluating XEN-D0501 in 46 obese participants.
- Idiopathic overactive bladder (OAB): an earlier Phase 2a trial studied two doses of XEN-D0501 in patients with idiopathic OAB.
How is XEN-D0501 given?
XEN-D0501 is given orally. In the current obesity trial, the intervention is listed as XEN-D0501 (ORAL). In the earlier overactive bladder trial, participants received XEN-D0501 twice daily at doses of 2 mg or 4 mg. The placebo in the obesity trial contains the same excipients and is identical to XEN-D0501 in appearance.
What do the clinical trials show?
One trial for XEN-D0501 is listed in the EU Clinical Trials Information System. It is a Phase 1, randomised, double-blind, placebo-controlled, parallel-group trial lasting 12 weeks in 46 participants with obesity. The primary outcomes are the frequency, seriousness and intensity of adverse events, and clinically significant changes from baseline in vital signs, ECG, clinical laboratory measurements and physical examination findings. The trial is currently authorised.
A separate Phase 2a study, reported by the Health Research Authority, evaluated the safety and efficacy of two doses of XEN-D0501 in idiopathic overactive bladder. That trial had a 14-day single-blind placebo run-in period, followed by 28 days of double-blind treatment with XEN-D0501 2 mg, XEN-D0501 4 mg or placebo, all given twice daily.
What side effects are known?
The current obesity trial is specifically measuring the frequency, seriousness and intensity of adverse events, along with changes in vital signs, ECG, laboratory measurements and physical examination findings. No specific side effects of XEN-D0501 are reported in the provided sources. The earlier overactive bladder summary notes that OAB is not life-threatening and therefore poses no long-term risk to subjects in that study, but it does not list individual side effects.